Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By
Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain
Presented by
Delvys Rodriguez-Abreu Universidad de Las Palmas de Gran Canaria, Spain
Conference
ELCC 2022
Trial
Phase 3, KEYNOTE-598
Doi
https://doi.org/10.55788/6101c6da
Although the addition of ipilimumab to first-line nivolumab improved overall survival (OS) of patients with metastatic non-small cell lung cancer (NSCLC), long-term results from KEYNOTE-598 demonstrated that adding ipilimumab to first-line pembrolizumab does not improve survival of patients with metastatic NSCLC and PD-L1 TPS ≥50%. Previously, results of the phase 3 CheckMate 227 trial (NCT02477826) showed that first-line dual immune blockade with nivolumab plus ipilimumab provides a durable, long-term OS benefit versus chemotherapy in patients with advanced NSCLC, regardless of PD-L1 expression or histology [1]. The phase 3 KEYNOTE-598 trial (NCT03302234) evaluated the efficacy and toxicity of first-line pembrolizumab plus ipilimumab versus pembrolizumab monotherapy in p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on